TAVR is being used in more patients to treat severe aortic stenosis. However, according to a new commentary piece, SAVR is still the smartest treatment option for certain populations, including younger patients with bicuspid aortic valves.

SCAI President James B. Hermiller, Jr., MD, detailed the group's key policy concerns in 2025 and beyond in a new video interview. 

The Sapien M3 device was designed to treat symptomatic mitral regurgitation in patients who are not suitable candidates for surgery or transcatheter edge-to-edge repair.

Cardiology still ranks No. 4 overall, trailing just orthopedics, radiology and plastic surgery.

Advancements in radiofrequency (RF) catheter ablation technology have been incremental over the past 30 years in efforts to improve safety, procedural efficiency and patient outcomes. While some newer technologies have gained a lot of attention in electrophysiology (EP) over the past several years, RF remains the solid frontline treatment.

Older heart failure patients with no immediate family are especially vulnerable. Additional interventions may be necessary to reach these patients and provide the best care possible.

The study's authors focused on blood pressure reductions and arterial stiffness, sharing their findings in Current Developments in Nutrition.

Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.  

Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.

Monoclonal antibody therapies will be the first drugs permitted to take advantage of alternatives, including advanced lab simulations and artificial intelligence. A pilot framework to phase out the decades-long requirement for animal testing will be rolled out in the coming year, the FDA said.

RBMA board member Kit Crancer offers an update on Medicare reform and advocacy in Congress and how medical societies may be able to get more traction in state legislatures.